I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Find a Research Lab
Jean Kim Lab
The Jean Kim Laboratory performs translational research in the
area of chronic rhinosinusitis, with a niche interest in the pathogenesis of hyperplastic nasal
polyposis. Studies encompass clinical research to basic wet laboratory research in
studying the underlying immune and autoimmune mediated mechanism of polyp growth and
perpetuation of disease. Human cell and tissue culture models are used. Techniques in the
laboratory include cell and tissue culture, real time PCR, immunoblot, ELISA, flow cytometry,
immunohistochemistry, electron microscopy, gene array analysis, and other molecular
approaches including genetic knockdowns. Approaches used in Dr. Kim’s clinical study
designs include prospective and retrospective analysis of patient outcomes and clinical
biomarkers, as wells controlled clinical trials.
While there has been an explosion of knowledge about human carcinogenesis over the last 2 decades, unfortunately, this has not translated into the development of effective therapies for either preventing or treating the common human cancers. The goal of the Isaacs’ lab is to change this situation by translating theory into therapy for solid malignancies, particularly Prostate cancer. Presently, a series of drugs discovered in the Isaacs’ lab are undergoing clinical trials in patients with metastatic cancer.
The ongoing drug discovery in the lab continues to focus upon developing agents to eliminate the cancer initiating stem cells within metastatic sites of cancer. To do this, a variety of bacterial and natural product toxins are being chemically modified to produce “prodrugs” whose cytotoxicity is selectively activated by proteases produced in high levels only by cancer cells or tumor associated blood vessel cells. In this way, these prodrugs can be given systemically to metastati...c patients without un-acceptable toxicity to the host while being selectively activated to potent killing molecules within metastatic sites of cancer.
Such a “Trojan Horse” approach is also being developed using allogeneic bone marrow derived Mesenchymal Stem cells which are genetically engineered to secrete “prodrugs” so that when they are infused into the patient, they selectively “home” to sites of cancers where the appropriate enzymatic activity is present to liberate the killing toxin sterilizing the cancer “neighborhood”. view more
Kathryn Carson Lab
The Kathryn Carson Lab investigates ways to improve medical research, particularly in the areas of brain and thyroid cancer, Alzheimer’s disease, atherosclerosis, hypertension, HIV and lupus. Our team seeks to help researchers optimize their studies through better study design, protocol and grant writing, data cleaning and analysis, and publication writing. We work with investigators from a wide range of departments through the Johns Hopkins Institute for Clinical and Translational Research.
Kawsar Rasmy Talaat Lab
Research in the Kawsar Rasmy Talaat Lab focuses on international health and parasitology, with an emphasis on vaccines, avian influenza and pandemic influenza. Our team conducts clinical trials of vaccines for a range of diverse pathogens, including flu strains that have the potential to reach pandemic status. Our studies seek to evaluate the safety and immunogenicity of vaccine candidates. We also have a longstanding interest in tropical medicine.
Kayode Williams Lab
The Kayode Williams Lab conducts translational research on neuromodulation. We primarily examine the mechanisms and efficacy of spinal cord stimulation in treating neuropathic pain, peripheral neuropathies and peripheral vascular disease. Our clinical trials explore spinal cord stimulation in the treatment of painful diabetic neuropathy and the treatment of critical non-reconstructible critical leg ischemia. We also have a longstanding interest in the business of medicine and seek to enhance value propositions for hospitals and physician groups through more effective management of resources.
Research focuses on clinical pharmacology of new anti-tuberculosis regimens with an emphasis on: (1) Phase I clinical trials of new or existing anti-TB drugs including dose escalation trials and studies of drug-drug interactions between anti-TB agents and antiretrovirals to treat HIV; (2) Use of PK/PD analysis and modelling in Phase II tuberculosis clinical treatment trials to determine concentration-effect relationships that will allow for optimization of dosing; and (3) Evaluation of TB and HIV drug concentrations in special populations, such as pregnant women and children; (4) Evaluation of treatment-shortening regimens for drug-sensitive TB and investigational regimens for treatment of multidrug-resistant TB; and (5) Translational work involving novel animal models of cavitary pulmonary TB disease to understand drug distribution in diseased lung.
The Laura Hummers Lab participates in a number of clinical trials and clinical investigations at the Scleroderma Center at Johns Hopkins. We have a particular interest in the predictors of outcomes in scleroderma. We’ve established a prospective cohort of 300 scleroderma patients to identify incident vascular outcomes in the hopes of identifying new biomarkers for disease development and progression.
Lee Bone Lab
Research in the Lee Bone Lab uses community-based participatory approaches to promote health in underserved urban African-American populations. We conduct randomized clinical trials on cardiovascular disease, diabetes and cancer detection and control in order to test the success of community interventions. We focus in particular on making interventions sustainable and on implementing electronic education to improve communication.
Liudmila Cebotaru Lab
Research in the Liudmila Cebotaru Lab studies cystic fibrosis transmembrane conductance regulator (CFTR) mutants. We also investigate corrector molecules that are currently in clinical trials to get a better understanding of their mechanism of action. A major focus of our research is on developing more efficient gene therapy vectors with the ultimate goal of developing a gene therapy for cystic fibrosis.
Lonny Yarmus Lab
Clinical trials conducted in the Lonny Yarmus Lab focus primarily on minimally-invasive diagnostic testing for patients with lung cancer and local therapy options for malignant airway obstructions. We investigate ways to improve the early diagnosis of lung cancer, as well as the treatment of later-stage cancer, using the least invasive methods possible. We are also part of the LIBERATE clinical study for patients who have difficulty breathing and suffer from severe emphysema.
Work in the Marek Mirski lab explores the subcortical mechanisms of seizure propagation and cortical synchrony. The primary goal of our research is to develop methodologies for inhibiting seizures using site-specific subcortical electrical stimulation. Our identification of synaptically linked subcortical elements that contribute to seizure propagation has led to FDA-sanctioned phase III clinical trials to assess the use of targeted thalamic stimulation in patients with intractable seizures. We also conduct clinical research on the treatment of acute head injury, elevated intracranial pressure, cerebral edema, ischemic stroke and ICU sedation.
Research in the Mark Sulkowski Lab focuses on hepatitis B and hepatitis C. We've conducted clinical research related to the management of viral hepatitis, including novel agents. Other studies focus on adult patients at the Johns Hopkins site of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Hepatitis B Clinical Research Network as well as the National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group.
Maureen Horton Lab
The Maureen Horton Lab conducts research on pulmonary fibrosis through the use of both preclinical models and human trials. Our studies have helped to develop novel, genetic, tissue-specific models of immune dysfunction, which have aided in defining the immune regulation of fibrosis and in the development of treatment strategies. We have used T-cell skewing immunotherapy to prevent and reverse chemical-induced lung fibrosis and have conducted clinical trials for idiopathic pulmonary fibrosis (IPF), which led to one of the first treatments that helped to improve quality of life in IPF patients.
Molecular Oncology Laboratory
Our Molecular Oncology lab seeks to understand the genomic wiring of response and resistance to immunotherapy through integrative genomic, transcriptomic, single-cell and liquid biopsy analyses of tumor and immune evolution. Through comprehensive exome-wide sequence and genome-wide structural genomic analyses we have discovered that tumor cells evade immune surveillance by elimination of immunogenic mutations and associated neoantigens through chromosomal deletions. Additionally, we have developed non-invasive molecular platforms that incorporate ultra-sensitive measurements of circulating cell-free tumor DNA (ctDNA) to assess clonal dynamics during immunotherapy. These approaches have revealed distinct dynamic ctDNA and T cell repertoire patterns of clinical response and resistance that are superior to radiographic response assessments. Our work has provided the foundation for a molecular response-adaptive clinical trial, where therapeutic decisions are made not based on imaging but b...ased on molecular responses derived from liquid biopsies. Overall, our group focuses on studying the temporal and spatial order of the metastatic and immune cascade under the selective pressure of immune checkpoint blockade with the ultimate goal to translate this knowledge into “next-generation” clinical trials and change the way oncologists select patients for immunotherapy. view less
Nicholas Rowan Lab
Dr. Rowan is actively involved in both outcomes and translational research relating to chronic rhinosinusitis and endoscopic skull base surgery. He has a keen interest patient-reported quality of life outcomes as well as those that pertain to smell and taste. Dr. Rowan is also involved in sinus-related clinical trials, pursuing new medical therapies and technological advancements for the treatment of patients with chronic rhinosinusitis.
Richard Chaisson Lab
Research in the Richard Chaisson Lab primarily examines tuberculosis and HIV infection, with specific focus on global epidemiology, clinical trials, diagnostics and public health interventions. Our recent research has involved evaluating a molecular diagnostic test for tuberculosis in HIV patients; observing TB responses during treatment of pulmonary tuberculosis; and examining antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in Southern Africa.
Robert Wise Lab
The Robert Wise Lab conducts clinical trials to study chronic obstructive lung diseases (COPD). We investigate inhaled corticosteroids in patients with mild to moderate COPD and the effectiveness of anti-inflammatories in allowing lung growth in mild to moderate asthmatic children. Our research includes exploring the efficacy of various treatments for asthmatic women who are pregnant and of lung-volume reduction surgery for emphysema patients. We also conduct studies of the clinical epidemiology, pathobiology and treatment of interstitial lung disease in patients with scleroderma.
Roy Brower Lab
The Roy Brower Lab conducts clinical trials related to the management of acute respiratory distress syndrome (ARDS). Our research also involves oxygen toxicity, a potentially fatal condition caused by too much supplemental oxygen.
Saleh Alqahtani Lab
The Saleh Alqahtani Lab has conducted clinical research on the management of fatty liver disease and viral hepatitis, including novel therapies. We’ve also been involved in various clinical trials related to liver cirrhosis, liver cancer and outcomes of liver transplant patients.
Sherita Golden Lab
Research in the Sherita Golden Lab focuses on identifying endocrine risk factors associated with the development of diabetes and cardiovascular disease. We conduct our research by incorporating measures of hormonal function into the design of clinical trials of cardiovascular risk modification, observational studies of incident cardiovascular disease and diabetes, and studies evaluating diabetic complications.